Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations

被引：1
|
作者：
Feng, J. [1 ]
Hueniken, K. [2 ]
Fan, Z. [1 ]
Faour, E. [1 ]
Corke, L. [1 ]
Leighl, N. [1 ]
Liu, G. [1 ]
Bradbury, P. [1 ]
Sacher, A.
Eng, L.
Stockley, T. [3 ]
Tsao, M-S. [1 ]
Shepherd, F. A. [1 ]
机构：
[1] UHN Univ Hlth Network, Med Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] UHN Univ Hlth Network, Biostast, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] UHN Univ Hlth Network, Lab Med Program, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1353P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
    Labbe, Catherine
    Cabanero, Michael
    Korpanty, Grzegorz J.
    Tomasini, Pascale
    Doherty, Mark K.
    Mascaux, Celine
    Jao, Kevin
    Pitcher, Bethany
    Wang, Rick
    Pintilie, Melania
    Leighl, Natasha B.
    Feld, Ronald
    Liu, Geoffrey
    Bradbury, Penelope Ann
    Kamel-Reid, Suzanne
    Tsao, Ming-Sound
    Shepherd, Frances A.
    LUNG CANCER, 2017, 111 : 23 - 29
  • [2] Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC)
    Chi, Jie
    Gandhi, Nishant
    Halmos, Balasz
    Liu, Stephen V.
    Ma, Patrick C.
    Elliott, Andrew
    Vanderwalde, Ari M.
    Mamdani, Hirva
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] KRAS/TP53 Co-Mutation is Associated with Increased Tumor Immunogenicity in Non-Small Cell Lung Cancer Patients
    Principe, Daniel R.
    Pasquinelli, Mary M.
    Ryan Nguyen
    Feldman, Lawrence
    Weinberg, Frank
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E44 - E44
  • [4] TP53 and ATM co-mutation predicts response to immune checkpoint inhibitors in non-small cell lung cancer
    Chen, Y.
    Chen, G.
    Li, J.
    Huang, C.
    Li, Y.
    Lin, J.
    Chen, L. Z.
    Lu, J. P.
    Wang, Y. Q.
    Wang, C. X.
    Pan, L. K.
    Xia, X. F.
    Yi, X.
    Chen, C. B.
    Zheng, X. W.
    Guo, Z. Q.
    Pan, J. J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] The Prediction Performance of TP53 / RB1 Co-Mutation on Small-Cell Lung Cancer Transformation in Patients With Non-Small Cell Lung Cancer
    Fan, Z.
    Mao, Z.
    Yuan, M.
    Chen, R.
    Xia, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1153 - S1153
  • [6] TP53/KMT2C Co-Mutation as a Novel Biomarker for Immunotherapy in Non-Small Cell Lung Cancer Patients
    Zhou, Q.
    Peng, X.
    Wang, W.
    Wang, W.
    Zhang, L.
    Wang, K.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S716 - S716
  • [7] TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
    Lee, Eung Bae
    Jin, Guang
    Lee, Shin Yup
    Park, Ji Young
    Kim, Min Jung
    Choi, Jin Eun
    Jeon, Hyo Sung
    Cha, Seung Ick
    Cho, Sukki
    Kim, Chang Ho
    Park, Tae-In
    Jung, Tae Hoon
    Son, Ji-Woong
    Park, Jae Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 698 - 705
  • [8] TP53 mutation, allelism and survival in non-small cell lung cancer
    Nelson, HH
    Wilkojmen, M
    Marsit, CJ
    Kelsey, KT
    CARCINOGENESIS, 2005, 26 (10) : 1770 - 1773
  • [9] TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Le, Xiuning
    Molife, Cliff
    Leusch, Mark S. S.
    Rizzo, Maria Teresa
    Peterson, Patrick M. M.
    Caria, Nicola
    Chen, Yongmei
    Gugel, Elena Gonzalez
    Visseren-Grul, Carla
    CANCERS, 2022, 14 (24)
  • [10] Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review
    Zhang, Chi
    Yang, Chao
    Shi, Qingming
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 65 - 82
12345